In the medical and general-healthcare arena, it’s no secret that diabetes is serious disease that affects a more than significant sample of the global human population. The illness, directly related to pancreatic function, can range from mild to severe, controllable to uncontrollable.
If managed properly via medication, diet, and exercise and regular monitoring of blood glucose levels, most people can live perfectly productive, long, and happy lives. The operative concept is “IF” individuals monitor their blood glucose levels and follow the regimen of care, they can control their condition. In some case, if caught early at onset, some may even be cured.
At any rate, with so many people diagnosed with diabetes, there is a rather large market for medications, and an even greater demand/market for devices that can monitor glucose levels and other parameters related to diabetes. One company making inroads to helping patients outsmart diabetes. Medtronic’s Guardian Connect CGM System is the only standalone continuous glucose monitoring (CGM) system. Helping patients on multiple daily injections, the system’s smart technology predicts where glucose levels are headed and alerts patients from 10 to 60 minutes before a glucose excursion, so they can act in advance.
You can see the system in action as well as get an even better grasp on CGM strategies at Medical Sensors Design Conference 2018 in San Jose CA. CGM is a critical component in improving outcomes in patients with Type 1 and Type 2 diabetes. To really get an expert’s eye view of this important healthcare issue, attend the “Driving Better Patient Outcomes in Diabetes: Continuous Glucose Monitoring (CGM) Using a Subcutaneous Electrochemical Sensor” session, Monday, June 25, 2018 at 3:00 PM.
Ellis Garai, Principal Biomedical Engineer at Medtronic, will discuss the function and construction of the company’s electrochemical biosensor and diagnostic algorithms specific to the Guardian Sensor. The sensor is part of a hybrid closed-loop system that automatically modulates basal insulin based on sensor glucose values.
Ellis Garai currently works in the Sensor R&D group at Medtronic Diabetes division in California. He has supported the launch of the Guardian Sensor CGM sensor, which is used in conjunction with the 670G system, the first hybrid closed-loop insulin delivery system.
Prior to Medtronic Ellis worked for Advanced Bionics (acquired by Boston Scientific) as part of the R&D and Emerging Indications Team and has also worked in product development at IDEO as well as Vibrynt, an early stage medical device company that was spun out of a Silicon Valley medical device incubator, ExploraMed. Ellis was also an Innovation Fellow in the Stanford Biodesign Innovation Fellowship out of which he co-founded BioTrace Medical.
Ellis holds a B.S. in Mechanical Engineering with a concentration in design and manufacturing from UCLA, a M.S. in Mechanical Engineering from Stanford University with a focus in mechatronics and medical device design, and completed his PhD in Mechanical Engineering at Stanford with a thesis on opto-electromechanical medical devices.
Once again, to gain this incredible wealth of knowledge, you need to do that two-step dance:
- Register for Medical Sensors Design Conference 2018 and/or Sensors Expo & Conference 2018
- Attend the “Driving Better Patient Outcomes in Diabetes: Continuous Glucose Monitoring (CGM) Using a Subcutaneous Electrochemical Sensor” session, Monday, June 25, 2018 at 3:00 PM.
